City Of Bandung Assigned 'BB-' Rating; Outlook Stable Dec 11

  • ID: 2031102
  • December 2011
  • Standard & Poors
1 of 3

Bandung operates in an evolving intergovernmental system with low systemic support. We note the city's limited financial flexibility, weak debt management, and poor management of government-related entities. Bandung has a fairly diversified local economy but low income by international standards, a low debt level, and an adequate liquidity profile, in our view. We are assigning our 'BB-' issuer credit rating to Bandung. The outlook is stable as we expect the city's budgetary outcomes and debt levels to stay within our projections. SINGAPORE (Standard & Poor's) Dec. 13, 2011--Standard & Poor's Ratings Services assigned its 'BB-' issuer credit rating to the City of Bandung. The outlook is stable. We also assigned our 'axBB+' ASEAN regional scale rating to the city. "The...

Companies mentioned in this report are: City of Bandung
Action: New Rating
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

City of Bandung

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.